...
search icon
insm-img

Insmed Inc, Common Stock

INSM

NSQ

$79.377

+$0.44

(0.56%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$14.29B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
506.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.28
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$21.92 L
$84.91 H
$79.377

About Insmed Inc, Common Stock

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINSMSectorS&P500
1-Week Return6.62%1.6%1.47%
1-Month Return-5.83%0.36%-7.51%
3-Month Return13.73%7.81%-3.27%
6-Month Return5.3%-5.77%-0.68%
1-Year Return202.1%0.78%9.62%
3-Year Return240.99%7.67%27.18%
5-Year Return423.13%78.63%136.6%
10-Year Return258.82%97.02%171.37%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue164.41M188.46M245.36M305.21M363.71M[{"date":"2020-12-31","value":45.2,"profit":true},{"date":"2021-12-31","value":51.82,"profit":true},{"date":"2022-12-31","value":67.46,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue39.87M44.15M55.13M65.57M85.74M[{"date":"2020-12-31","value":46.5,"profit":true},{"date":"2021-12-31","value":51.49,"profit":true},{"date":"2022-12-31","value":64.29,"profit":true},{"date":"2023-12-31","value":76.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit124.54M144.31M190.23M239.63M277.96M[{"date":"2020-12-31","value":44.8,"profit":true},{"date":"2021-12-31","value":51.92,"profit":true},{"date":"2022-12-31","value":68.44,"profit":true},{"date":"2023-12-31","value":86.21,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin75.75%76.57%77.53%78.52%76.43%[{"date":"2020-12-31","value":96.48,"profit":true},{"date":"2021-12-31","value":97.53,"profit":true},{"date":"2022-12-31","value":98.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":97.34,"profit":true}]
Operating Expenses389.77M512.07M668.36M949.26M1.16B[{"date":"2020-12-31","value":33.71,"profit":true},{"date":"2021-12-31","value":44.29,"profit":true},{"date":"2022-12-31","value":57.81,"profit":true},{"date":"2023-12-31","value":82.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(265.23M)(367.76M)(478.12M)(709.63M)(878.25M)[{"date":"2020-12-31","value":-26523200000,"profit":false},{"date":"2021-12-31","value":-36776000000,"profit":false},{"date":"2022-12-31","value":-47812300000,"profit":false},{"date":"2023-12-31","value":-70962600000,"profit":false},{"date":"2024-12-31","value":-87825200000,"profit":false}]
Total Non-Operating Income/Expense(57.02M)(101.79M)(28.47M)(119.08M)(116.73M)[{"date":"2020-12-31","value":-5702000000,"profit":false},{"date":"2021-12-31","value":-10179100000,"profit":false},{"date":"2022-12-31","value":-2847400000,"profit":false},{"date":"2023-12-31","value":-11908000000,"profit":false},{"date":"2024-12-31","value":-11672600000,"profit":false}]
Pre-Tax Income(292.69M)(436.41M)(480.15M)(747.01M)(910.07M)[{"date":"2020-12-31","value":-29268800000,"profit":false},{"date":"2021-12-31","value":-43641200000,"profit":false},{"date":"2022-12-31","value":-48015100000,"profit":false},{"date":"2023-12-31","value":-74701200000,"profit":false},{"date":"2024-12-31","value":-91006500000,"profit":false}]
Income Taxes1.40M(1.76M)1.38M2.56M3.71M[{"date":"2020-12-31","value":37.82,"profit":true},{"date":"2021-12-31","value":-47.42,"profit":false},{"date":"2022-12-31","value":37.31,"profit":true},{"date":"2023-12-31","value":68.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(294.09M)(434.65M)(481.53M)(749.57M)(913.77M)[{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false},{"date":"2024-12-31","value":-91377200000,"profit":false}]
Income From Continuous Operations(294.09M)(434.65M)(481.53M)(749.57M)(913.77M)[{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false},{"date":"2024-12-31","value":-91377200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(294.09M)(434.65M)(481.53M)(749.57M)(913.77M)[{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false},{"date":"2024-12-31","value":-91377200000,"profit":false}]
EPS (Diluted)(3.01)(3.64)(3.90)(5.34)(5.59)[{"date":"2020-12-31","value":-301,"profit":false},{"date":"2021-12-31","value":-364,"profit":false},{"date":"2022-12-31","value":-390,"profit":false},{"date":"2023-12-31","value":-534,"profit":false},{"date":"2024-12-31","value":-559,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INSM
Cash Ratio 4.82
Current Ratio 5.45
Quick Ratio 5.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INSM
ROA (LTM) -29.31%
ROE (LTM) -890.75%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INSM
Debt Ratio Lower is generally better. Negative is bad. 0.86
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.14

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INSM
Trailing PE NM
Forward PE NM
P/S (TTM) 39.28
P/B 48.83
Price/FCF NM
EV/R 37.53
EV/Ebitda NM
PEG NM

FAQs

What is Insmed Inc share price today?

Insmed Inc (INSM) share price today is $79.377

Can Indians buy Insmed Inc shares?

Yes, Indians can buy shares of Insmed Inc (INSM) on Vested. To buy Insmed Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INSM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Insmed Inc be purchased?

Yes, you can purchase fractional shares of Insmed Inc (INSM) via the Vested app. You can start investing in Insmed Inc (INSM) with a minimum investment of $1.

How to invest in Insmed Inc shares from India?

You can invest in shares of Insmed Inc (INSM) via Vested in three simple steps:

  • Click on Sign Up or Invest in INSM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Insmed Inc shares
What is Insmed Inc 52-week high and low stock price?

The 52-week high price of Insmed Inc (INSM) is $84.91. The 52-week low price of Insmed Inc (INSM) is $21.92.

What is Insmed Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Insmed Inc (INSM) is 48.83

What is the Market Cap of Insmed Inc?

The market capitalization of Insmed Inc (INSM) is $14.29B

What is Insmed Inc’s stock symbol?

The stock symbol (or ticker) of Insmed Inc is INSM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top